CSCIF (Cosciens Biopharma) Accounts Payable: $0.59 Mil (As of Mar. 2026)


CSCIF Cosciens Biopharma Inc CSCIF
60 GF Score
Price $2.13
GF Value $2.39
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma Accounts Payable?

Cosciens Biopharma CSCIF +3.90% 60 Accounts Payable is $0.59 Mil as of Mar. 2026. GuruFocus rates CSCIF with a GF Score™ of 60/100 and a GF Value™ of $2.39 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Cosciens Biopharma's Accounts Payable for the quarter that ended in Mar. 2026 was $0.59 Mil.

Cosciens Biopharma's quarterly Accounts Payable declined from Sep. 2025 ($1.03 Mil) to Dec. 2025 ($0.75 Mil) and declined from Dec. 2025 ($0.75 Mil) to Mar. 2026 ($0.59 Mil).

Cosciens Biopharma's annual Accounts Payable increased from Dec. 2023 ($0.28 Mil) to Dec. 2024 ($2.41 Mil) but then declined from Dec. 2024 ($2.41 Mil) to Dec. 2025 ($0.75 Mil).

Cosciens Biopharma Accounts Payable Related Terms

Cosciens Biopharma Accounts Payable Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Accounts Payable Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.28 2.41 0.75

Cosciens Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.86 1.54 1.03 0.75 0.59
CSCIF
60GF Score
Cosciens Biopharma Inc CSCIF
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $0.59 Mil mean?
Cosciens Biopharma (CSCIF) has a Accounts Payable of $0.59 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Accounts Payable too high?
Cosciens Biopharma's current Accounts Payable is $0.59 Mil. Overall, Cosciens Biopharma has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Accounts Payable compare to VRTX and REGN?
Cosciens Biopharma's Accounts Payable of $0.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Accounts Payable is $0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.39, compared to a current price of $2.13 — trading 10.9% below its estimated fair value. The current Accounts Payable is $0.59 Mil. Cosciens Biopharma's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Accounts Payable is $0.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $2.13 is trading 10.9% below its estimated GF Value™ of $2.39. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • Accounts Payable: $0.59 Mil
  • GF Value™: $2.39 vs. price of $2.13 (10.9% below fair value)
  • GF Score™: 60/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
60GF Score

Get the complete analysis for CSCIF

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price
$2.39
GF Value